Logo
x

Search

Subscribe Now

Novartis

Novartis Highlights the P-III (REMIX) Trial Data of Remibrutinib to Treat Chronic Spontaneous Urticaria at EAACI 2024

Novartis Highlights the P-III (REMIX) Trial Data of Remibrutinib to Treat Chronic Spontaneous Urticaria at EAACI 2024

  • May 31, 2024
Novartis Highlights Results from the P-III (ALIGN) Study of Atrasentan for the Treatment of IgA Nephropathy (IgAN) at ERA 2024

Novartis Highlights Results from the P-III (ALIGN) Study of Atrasentan for the Treatment of IgA Nephropathy (IgAN) at ERA 2024

  • May 27, 2024
Novartis to Acquire Mariana Oncology, Expanding its Radioligand Therapy Pipeline

Novartis to Acquire Mariana Oncology, Expanding its Radioligand Therapy Pipeline

  • May 3, 2024
Novartis Reports Data from the P-III Study of Fabhalta (iptacopan) for the Treatment of IgA Nephropathy (IgAN)

Novartis Reports Data from the P-III Study of Fabhalta (iptacopan) for the Treatment of IgA Nephropathy (IgAN)

  • April 16, 2024
Novartis Reports Results from the P-IIIb (V-INITIATE) Study of Leqvio for Treating Atherosclerotic Cardiovascular Disease (ASCVD)

Novartis Reports Results from the P-IIIb (V-INITIATE) Study of Leqvio for Treating Atherosclerotic Cardiovascular Disease (ASCVD)

  • April 8, 2024
Novartis Reports the CHMP’s Positive Opinion for Fabhalta (iptacopan) to Treat Paroxysmal Nocturnal Hemoglobinuria (PNH)

Novartis Reports the CHMP’s Positive Opinion for Fabhalta (iptacopan) to Treat Paroxysmal Nocturnal Hemoglobinuria (PNH)

  • March 22, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.